Zobrazeno 1 - 10
of 60
pro vyhledávání: '"L Gumbrell"'
Autor:
Duncan I. Jodrell, Tim Meyer, Jenny Wu, Margaret Cobb, John A. Hartley, Victoria J. Spanswick, L Gumbrell, Daniel Hochhauser, Peter H. Clingen, Richard H. J. Begent, Paul M. Loadman
Publikováno v:
Clinical Cancer Research. 15:2140-2147
Purpose: This phase I dose-escalation study was undertaken to establish the maximum tolerated dose of the sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. The study also investigated antitumor activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33a58ec3095d2b31b625b3defd15355
https://doi.org/10.1158/1078-0432.ccr-08-1315
https://doi.org/10.1158/1078-0432.ccr-08-1315
Autor:
Malcolm R Ranson, T. Brian H. McMurry, R. Stanley McElhinney, Martin J Dawson, Siow Ming Lee, Helen McGrath, J Bridgewater, L Gumbrell, Mark R Middleton, Geoffrey P. Margison, Dorothy Josephine Donnelly, Sue Waller, Debra Jowle, Gavin Halbert
Publikováno v:
Clinical Cancer Research. 12:1577-1584
Purpose: A major mechanism of resistance to temozolomide involves the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (ATase). The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde10c57e9db41a7dfa6b677c78520e0
https://doi.org/10.1158/1078-0432.ccr-05-2198
https://doi.org/10.1158/1078-0432.ccr-05-2198
Autor:
Michael R.L. Stratford, K Bellenger, Susan M. Galbraith, L Gumbrell, S Waller, Paul M. Loadman, G. J. S. Rustin, Gavin Halbert, L Folkes, C Bradley
Publikováno v:
British Journal of Cancer
The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA). In all, 46 patients received a total of 247 infu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8e2780436c2381fa3b0a3c24317c19
https://doi.org/10.1038/sj.bjc.6600885
https://doi.org/10.1038/sj.bjc.6600885
Autor:
C Gardner, M Brannan, Malcolm R Ranson, Sue Cheeseman, Parveen Khan, L Gumbrell, Alan T McGown, D Dickens
Publikováno v:
British Journal of Cancer
CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of intracellular phosphatidic acid. We treated 30 patients as part of a Phase I and pharmacokinetic study to determine the maximum-tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225e54a29d6b1c176850d7d56b3d789f
http://europepmc.org/articles/PMC2363467
http://europepmc.org/articles/PMC2363467
Autor:
Alan Hilary Calvert, Michael Millward, I. Middleton, F Chapman, E. Mccann, Mark R. Proctor, B. M. J. Cantwell, Michael J. Lind, D. Simmonds, L. Gumbrell
Publikováno v:
British Journal of Cancer
Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd025194af19f66ac48feef957444404
https://doi.org/10.1038/bjc.1995.118
https://doi.org/10.1038/bjc.1995.118
Autor:
L. Gumbrell, K. E. Jenns, Alan Hilary Calvert, S. B. Kaye, Martin A. Graham, David R. Newell, B. J. Foster
Publikováno v:
European Journal of Cancer. 28:463-469
The development of new drugs in early clinical trials is currently based upon the results of preclinical antitumour and toxicity studies in animals. More recently, the use of preclinical pharmacokinetic information in mice has been proposed to also p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb7700801c120badc30733e91b3dcf9
https://doi.org/10.1016/s0959-8049(05)80077-2
https://doi.org/10.1016/s0959-8049(05)80077-2
Autor:
Paul Thompson, M R McCrystal, L Gumbrell, D J Porter, Gavin Halbert, B. D. Evans, Vernon Harvey, Michael B. Jameson, Philip Kestell, Bruce C. Baguley, K Bellenger, M Small
Publikováno v:
British Journal of Cancer
The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8742741e40b4c2588265f94ea504b46
https://pubmed.ncbi.nlm.nih.gov/12799625
https://pubmed.ncbi.nlm.nih.gov/12799625
Autor:
L D Hope-Stone, D O'Malley, Hassan Shahbakhti, Surinder K. Sharma, E Tsiompanou, Ajw Hilson, Richard H. J. Begent, L Gumbrell, David C. Blakey, Daniel Hochhauser, K L Adamson, Janet Martin, A J Green, SD Webley, A Robbins, L Sena, R. J. Francis, Caroline J. Springer
Publikováno v:
British Journal of Cancer
Antibody-directed enzyme prodrug therapy is a targeted therapy in which a prodrug is activated selectively at the tumour site by an enzyme, which has been targeted to the tumour by an antibody (antibody-enzyme conjugate). Previous clinical trials hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f37d304ba68b96192d5ba70661f029
https://pubmed.ncbi.nlm.nih.gov/12237768
https://pubmed.ncbi.nlm.nih.gov/12237768
Autor:
L Gumbrell, Y Willems
Publikováno v:
Nursing Standard. 5:30-32
While there have been notable advances in the treatments and prognoses of certain types of cancer over recent years, the need for research to identify effective therapies for more resistant forms remains paramount. Yvonne Willems and Lindsey Gumbrell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11a34a2b72994cf9744f7eab3dc5cd08
https://doi.org/10.7748/ns.5.6.30.s38
https://doi.org/10.7748/ns.5.6.30.s38
Autor:
D. Simmons, E. Mccann, Michael Millward, D Sinha, Ghazal-Aswad S, I. Middleton, L Robson, F Dore-Green, F Chapman, A Oakey, Alan Hilary Calvert, N P Bailey, K Fishwick, Michael J. Lind, L. Gumbrell, Mark R. Proctor, D Craigs
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(3)
PURPOSE The aim of this study was to increase the dose intensity of carboplatin in women with International Federation of Gynecology and Obstetrics (FIGO) Stage Ic-IV epithelial ovarian cancer with the use of granulocyte colony-stimulating factor (G-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0151e434dd572ae2640ec978c07f879c
https://pubmed.ncbi.nlm.nih.gov/8622027
https://pubmed.ncbi.nlm.nih.gov/8622027